Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Hematologic Neoplasms 1

Interventions

fludarabine 6trametinib 5Specimen Handling 5Standard of Care 4Practice Guidelines as Topic 4Magnetic Resonance Spectroscopy 4fludarabine phosphate 3Whole-Body Irradiation 3Mycophenolic Acid 3Melphalan 3Interviews as Topic 3GSK2636771 3Cyclophosphamide 3Crizotinib 3Busulfan 3Biopsy 3Antilymphocyte Serum 3AP 1903 reagent 3venetoclax 2thymoglobulin 2palbociclib 2osimertinib 2letermovir 2dabrafenib 2capivasertib 2binimetinib 2adavosertib 2X-Rays 2Thiotepa 2Tacrolimus 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Hematologic Neoplasms × LY2784544 × Clear all
NCT01594723 2025-07-23

A Study of LY2784544 in Participants With Myeloproliferative Neoplasms

Eli Lilly and Company

Phase 2 Active not recruiting
110 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡